Metabolic Genetic Testing Market size is expected to expand at around 8.1% CAGR during the forecast period i.e., between 2024-2036. The metabolic genetic testing market is expected to grow on a robust note in the next decade. Moreover, the next decade will see the integration of telehealth services with the physical ones that exist at the moment. The urgent and primary care are bound to be accessed through virtual visits, along with improvement in collaboration with the clinics, dialysis centers, long-term care facilities, and mental health services. Therefore, this transition will soon be visible in the healthcare sector. Next-generation sequencing is the emerging method that is currently used for DNA sequencing. The change in lifestyle during the past years has increased the possibility of metabolic and genetic disorders. The increasing incidence of numerous genetic and metabolic problems is another factor. According to estimates in the year 2020, the percentage of people in the United States with metabolic syndrome has risen to 37%.
Metabolic genetic disorders are caused due to either absence of any gene or presence of inactive gene leading to enzyme deficiency. These are also referred to as inborn metabolic errors. There are currently countless hereditary metabolic diseases. lysosomal storage diseases, mitochondrial disorders, disorders of metal metabolism, solar sensitivity, thyroid disease, etc., are a few of them. Diabetes also slows metabolism down by lowering insulin levels. As a result, the body is prevented from storing the energy it receives from food for later use. Additionally, genetic testing can aid in identifying the origin of chronic, frequently incapacitating symptoms that go undetected in patients with suspected metabolic abnormalities. To assist with diagnosis, specialized testing known as metabolic testing may be requested to examine the patterns of fat, glucose, and amino acid metabolism. Amino acids are the fundamental building blocks of proteins. The metabolic genetic testing market is driven by advancements in DNA sequencing techniques, increasing research in human genetics, and awareness about the testing techniques. This testing method provides an accurate course of treatment and specific investigations. In addition, Terumo Corporation and French Company Diabeloop signed an agreement for a strategic partnership. According to the new agreement, in addition to the current joint development of the AID system for Japan, they will work closely to bring Automated Insulin Delivery solutions to Europe with potential further global expansion. The demand for AID systems is high in the United States and Europe.
Growth Drivers
Challenges
The rise in the prevalence of genetic metabolic disorders, changes in lifestyle, technological developments in screening methods, public awareness of genetic testing, and increased research and development are additional factors contributing to the growth of the global market for metabolic, genetic testing. In DNA sequencing, numerous technological developments are taking place. There are currently countless hereditary metabolic diseases. Lysosomal storage diseases, mitochondrial disorders, disorders of metal metabolism, solar sensitivity, thyroid disease, etc., are a few of them. In April 2019, Centogene N.V launched a panel for detection of rare metabolic disease, combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions.
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
8.1% |
|
Regional Scope |
|
The market for global metabolic genetic testing market is segmented by technique, out of which, over the projected period, the next-generation sequencing segment is expected to hold the highest share. The NGS market is expanding as a result of a number of factors, including ongoing technological advancements in sequencers and the widespread adoption of NGS technologies owing to their low cost and high efficiency. For instance, DNA Script is enabling their partners to explore the combined use of enzymatic synthesis of DNA and next-generation sequencing to enable accurate and low-cost decoding an important step to transitioning from digital to biology-based data storage.
Our in-depth analysis of the global metabolic genetic testing market includes the following segments:
|
By Technique |
|
|
By Indication |
|
|
By End User |
|
The global metabolic genetic testing market is segmented into five major regions, including North America, Europe, Asia Pacific, Middle East & Africa region, and Latin America. North America industry is estimated to dominate majority revenue share by 2036, as the region has major manufacturing and laboratories companies, and an increase in investments in new techniques. Moreover, the governmental initiatives for genetic testing and increase in funding act as a driver for the market. For instance, according to the World Bank data, North America's current health expenditure (% of GDP) increased from 12.2% in 2000 to 16.32% in 2019, growing at an average annual rate of 1.57%. Further, many regional companies are involved in strategic partnerships to enhance their product portfolios through research and development activities.
Eli Lilly and Company announced the acquisition of Protomer Technologies - a private biotech company. Protomer's proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.
Lumen (Metaflow LTD) announced the discovery of metabolism tracking wellness device that provides real time data with person’s breath and also help in maintaining fitness, weight loss, and others.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?